Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. Necessary
Throughout the year, we cover business news of all kinds openings, closings, mergers, transactions you name it, and we are probably covering it. But while executives and kingmakers often are the subject of headlines, beneath every business story is a bunch of hard workers. And Top Workplaces is dedicated to those workers and the places that treat them best.
For the eighth year, The Oklahoman partnered with Philadelphia-based Energage to rank the Top Workplaces in Oklahoma. The process is based on a scientific survey of employees who rate their workplace culture. It also gives company insights about what makes them unique.
Share this article
NEW YORK, Jan. 27, 2021 /PRNewswire/
Q BioMed Inc. (OTCQB: QBIO), announced today that the U.S. Food and Drug Administration s Office of Orphan Products Development has granted Orphan Drug Designation to
Uttroside-B, a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. In preclinical studies, Uttroside-B was up to 10-times more potent against HCC cells than Sorafinib, the standard of care drug at the time.
As an Orphan Drug, Uttroside-B may benefit from a seven-year market exclusively following marketing approval, grant funding for clinical trials that contribute to marketing approval, protocol assistance, and tax credits. Preclinical testing is now underway to support an FDA Investigational New Drug (IND) application expected this year.
Published: Jan 26, 2021
NEW YORK, Jan. 26, 2021 /PRNewswire/ Q Biomed Inc. (OTCQB: QBIO), announces that it has received additional notices of patent allowances from both Canada and Japan for its Uttroside-B molecule intended to treat liver cancer. The patent titled Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma is a Method Of Use patent that covers the use of Uttroside-B for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. International and additional U.S. claims are currently under prosecution for the technology which addresses a severe unmet need for a safe and effective drug to treat HCC.
By Camille Noe Pagán
If you have multiple sclerosis (MS), you might be wondering if you’ll have to be on medication for the rest of your life. That’s something only you and your doctor can decide together. But some people do choose to stop taking disease-modifying medications for MS for a while. Some even quit their medication for good.
There are several reasons why you might stop taking MS medication. You may feel it doesn’t do enough to ease your symptoms. Or maybe the side effects are too severe, or they outweigh the drug’s benefits. If you relapse while taking medication, you could feel that if it isn’t working, you shouldn’t bother using it.